Reaction

Underweight reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,938 reports · 32 co-occurring drugs

As of the last recalculation, Underweight appears in 1,938 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 19.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Teduglutide	24	19.4	19.4
Dimenhydrinate	15	15.2	15.2
Palivizumab	20	14.1	14.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	11	13.2	13.2
Methylprednisolone Acetate	8	10.8	10.8
Pancrelipase	36	10.2	10.2
Atazanavir	13	9.8	9.8
Ivacaftor	7	9.5	9.5
Raltegravir	14	9.2	9.2
Tobramycin	18	8.1	8.1
Zidovudine	10	8.1	8.1
Methylphenidate Hydrochloride	39	7.2	7.2
Amikacin	11	7.0	7.0
Paricalcitol	9	6.9	6.9
Emtricitabine And Tenofovir Disoproxil Fumarate	28	6.7	6.7
Lisdexamfetamine Dimesylate	20	6.6	6.6
Rivastigmine	11	6.3	6.3
Dornase Alfa	11	6.1	6.1
Atomoxetine Hydrochloride	12	5.4	5.4
Panitumumab	7	4.8	4.8
Elexacaftor, Tezacaftor, And Ivacaftor	5	4.3	4.3
Asfotase Alfa	4	4.3	4.3
Tenofovir Disoproxil Fumarate	13	4.2	4.2
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	3	3.9	3.9
Paliperidone Palmitate	11	3.7	3.7
Diroximel Fumarate	4	3.6	3.6
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	10	3.5	3.5
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	3	3.2	3.2
Somatropin	21	3.1	3.1
Dimethyl Fumarate	30	2.6	2.6
Abaloparatide	7	2.6	2.6
Natalizumab	40	2.4	2.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.